Flame spray pyrolysis for sensing at the nanoscale.

Progress in developing novel gas sensors based on semiconducting metal oxides (SMOX) has been hindered by the cumbersome fabrication technologies currently employed. They involve time intensive synthesis procedures for gaining sensitive materials and preparation of the inks employed for realizing sensing layers. In this paper we review the opportunities offered by the relatively young method of flame spray pyrolysis, with which it is possible not only to synthesize a broad selection of SMOX in pure or doped form, but also to simultaneously deposit thick and highly porous gas sensitive films on a variety of substrates. In less than ten years the properties of nine base materials have been evaluated for all most relevant target gases and the obtained results are promising for future development.

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

We tested the clinical efficacy of a biologically active dose (BAD) of interferon (IFN)-gamma for treatment of progressive renal cell carcinoma (RCC). Twenty-two RCC patients with disease progression subsequent to nephrectomy were entered on a phase II clinical trial. During an initial dose-finding phase, biochemical responses to repeated once-weekly subcutaneous injections of 10, 100, or 500 micrograms of recombinant IFN-gamma were tested in 16 patients. Results indicated that 100 micrograms IFN-gamma applied once weekly was biologically active with induction of serum beta 2-microglobulin and neopterin. Such a dose induced a nearly maximum response of both markers lasting more than 4 days. This dose was also associated with minimal side effects. A dose of 100 micrograms IFN-gamma given once weekly was, therefore, subsequently given weekly for long-term treatment. During a median time of therapy of 10 months (range, 2 to 32 months) two complete (CR; 20+, 20+ months) and four partial tumor responses (PR; 6+, 7+, 8+, 24+ months) were seen (30% CR plus PR; 95% confidence limits, 12% to 54%) among 20 patients evaluable for response. Patients with refractory disease had significantly lower IFN-gamma-induced increments of serum beta 2-microglobulin than those who achieved clinical remission or stable disease.

Increased levels of Met-enkephalin-like immunoreactivity in the spinal cord CSF of rats with adrenal medullary transplants.

Recent work in our laboratory has demonstrated that the transplantation of adrenal medullary tissue into the spinal cord subarachnoid space can reduce pain sensitivity, particularly following nicotinic stimulation. This analgesia most likely results from the release of opioid peptides from the implanted chromaffin cells since it is blocked by the opiate antagonist naloxone. The purpose of the present study was to more directly measure opioid peptide release from adrenal medullary implants in the spinal cord using spinal cord superfusions. Basal levels of Met-enkephalin-like immunoreactivity (MELI) in spinal cord superfusates of animals with adrenal medullary implants was twice that in animals with control implants. The injection of nicotine further increased MELI release in adrenal medullary, but not control implanted animals. Both the basal MELI levels and the MELI levels following nicotine were correlated with reduced pain sensitivity in animals with adrenal medullary implants. Morphological studies revealed good long-term survival of grafted chromaffin cells. Results of this study suggest that it is possible to increase opioid peptide levels and concomitantly decrease pain sensitivity by the transplantation of adrenal medullary tissue into the spinal cord subarachnoid space.

Adrenal medullary transplants increase spinal cord cerebrospinal fluid catecholamine levels and reduce pain sensitivity.

Previous work in this laboratory has shown that adrenal medullary transplants into the spinal cord subarachnoid space can reduce pain sensitivity. This analgesia most likely results from the release of neuroactive substances, particularly catecholamines and opioid peptides, from the transplanted cells into the CSF of the spinal cord, since it can be attenuated or blocked by alpha-adrenergic or opiate antagonists. The purpose of the present study was to more directly measure the release of catecholamines from adrenal medullary transplants in the spinal cord CSF using a spinal superfusion technique. CSF samples from rats with 6-month-old transplants were assayed for catecholamines using HPLC with electro-chemical detection. Results indicated that norepinephrine levels were increased threefold, and epinephrine levels nearly 100-fold, in animals with adrenal medullary transplants compared with control transplanted animals. There was no apparent increase in dopamine levels. Furthermore, the increased levels of total catecholamines were correlated with decreased pain sensitivity. Results of this study indicate that adrenal medullary transplants can survive for long periods in the rat spinal CSF and continue to release high levels of catecholamines. Together, the release of catecholamines and opioid peptides from adrenal medullary transplants may provide the ideal combination for the reduction of pain.

Isolation and growth of a bacterium able to degrade nitrilotriacetic acid under denitrifying conditions.

A Gram-negative bacterium was isolated from river sediment which was able to grow with nitrilotriacetic acid as a combined carbon, nitrogen and energy source in the absence of molecular oxygen using nitrate as the terminal electron acceptor. Batch growth parameters and mass balances are reported for growth under both aerobic and denitrifying conditions. The strain was characterized with respect to its substrate spectrum and other physiological properties. This denitrifying isolate is serologically unrelated to the comprehensively described Gram-negative obligately aerobic NTA-degrading bacteria all of which belong to the alpha-subclass of Proteobacteria. Chemotaxonomic characterization, which revealed the presence of spermidine as the main polyamine and ubiquinone Q-8, excludes the new isolate from the phylogenetically redefined genus Pseudomonas and indicates a possible location within the gamma-subclass of Proteobacteria close to, but separate from the genus Xanthomonas.